Pernix Therapeutics, a specialty pharmaceutical company, has announced the availability of Omeclamox-Pak to treat Helicobacter pylori (H. pylori) infection and duodenal ulcer disease (active or one-year history) to eradicate H. pylori in adult patients.
Omeclamox-Pak, a ten-day, triple combination oral therapy, is comprised of omeprazole delayed-release capsules (20mg), clarithromycin tablets (500mg) and amoxicillin capsules (500mg).
Pernix president and chief executive officer Cooper Collins said, "We are pleased to announce that Omeclamox-Pak is now available by prescription in pharmacies across the country, and physicians and patients will have another therapy option for the treatment of H. pylori and duodenal ulcer disease."
Omeprazole is an antisecretory drug, which works by decreasing the amount of acid the stomach produces.
The safety and effectiveness of Omeclamox-Pak in the paediatric population has not yet been established. The product was approved by the FDA in 2011.
